Wavelength-Selective Filtration in Photobiological Eyewear

Dubey S, Choudhary M (2026) | Zenodo Technical Report | 46+ Views | 37+ Downloads

DOI: 10.5281/zenodo.19422123  |  Read on Academia.edu

ipRGC Subtypes, Signalling Pathways & Implications for Eyewear Design

Dubey S, Choudhary M (2026) | Zenodo Technical Report | 22 Peer-Reviewed References

DOI: 10.5281/zenodo.19500137  |  Read on Academia.edu

Indian Patent IN 202521094370 | All 10 Claims Approved

Dual-band selective light attenuation technology. Simultaneously filters 460-490nm (melanopsin/ipRGC pain pathway) and 585-600nm (cone-driven pain pathway) while preserving the beneficial 520-560nm green band. Addresses both migraine pain mechanisms identified by Harvard research (Noseda et al., 2016). India's first granted patent in photobiological eyewear.

Indian Patent Application IN 202521120977

Peak-blocking circadian protection technology. Achieves 100% attenuation of blue light at the melanopsin activation peak, with comprehensive blocking extending to the 560nm upper boundary of the melanopsin sensitivity envelope. Engineered for maximum melatonin protection during evening screen use, based on the published action spectrum (Brainard et al., 2001, Journal of Neuroscience).

Suraj Dubey

Senior Optometrist, Researcher & Innovator

Founder & Head of R&D, Sleepaxa Private Limited. Inventor of NeuroCalm FLX+™ and Circadian560™. Named inventor on 4 Indian patents. Published researcher with peer-reviewed technical reports on photobiological lens design.

ORCID: 0009-0003-7510-9254

Dr. Monica Choudhary

Director MCVI | Ex-AIIMS Professor | Renowned Author & Optometrist

Founding Member, Clinical Advisory Board, Sleepaxa Private Limited. Former faculty at the All India Institute of Medical Sciences (AIIMS), New Delhi. Brings institutional-grade clinical oversight and academic rigour to all Sleepaxa lens technologies and published research.